Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06983028 · ClinicalTrials.gov registry record · Phase 2
Atacicept in Multiple Glomerular Diseases
A Phase 2 study of Nephrotic Syndrome and FSGS, sponsored by Vera Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06983028 is a Phase 2 study of Nephrotic Syndrome and FSGS that is actively recruiting participants, run by Vera Therapeutics. The registered enrollment target is 200 participants, below the 619-participant average among 7 other Nephrotic Syndrome trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06983028, a Phase 2 study of Nephrotic Syndrome and FSGS, is actively recruiting participants, sponsored by Vera Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.
Conditions Studied
Interventions
- DRUG Atacicept
Study Locations (1)
California
- Vera Therapeutics - Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-07-07 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06983028
The ClinicalTrials.gov registry entry for NCT06983028 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 619-participant average among 7 other Nephrotic Syndrome trials with a reported enrollment target (68% lower). The listed sponsor is Vera Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Nephrotic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Atacicept is the first listed.
NCT06983028 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06983028 about?
NCT06983028 is a clinical study titled "Atacicept in Multiple Glomerular Diseases". The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.
What is the current status of trial NCT06983028?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-07-07. Estimated completion is 2027-11.
What conditions does trial NCT06983028 study?
This clinical trial studies the following conditions: Nephrotic Syndrome, FSGS, IgAN, MCD, pMN.
What interventions are being tested in trial NCT06983028?
The interventions under investigation include: Atacicept (DRUG).
Who is sponsoring clinical trial NCT06983028?
This trial is sponsored by Vera Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06983028 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nephrotic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Belimumab With Rituximab for Primary Membranous Nephropathy
RECRUITING · Phase 2
-
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
RECRUITING · Phase 2
-
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
RECRUITING
-
Immune System Related Kidney Disease
RECRUITING
-
Diuretic Tuner Clinical Decision Support
RECRUITING · NA
-
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.